NCT06623890 A Study to Learn More About the Long-Term Safety of BIIB141 (Omaveloxolone) in Participants With Friedreich's Ataxia Who Are Prescribed it by Their Own Doctors
| NCT ID | NCT06623890 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Biogen |
| Condition | Friedreich Ataxia |
| Study Type | OBSERVATIONAL |
| Enrollment | 300 participants |
| Start Date | 2024-12-12 |
| Primary Completion | 2029-10-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 300 participants in total. It began in 2024-12-12 with a primary completion date of 2029-10-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
In this study, researchers will learn more about the safety of BIIB141, also known as omaveloxolone or SKYCLARYS®. This is a drug available for doctors to prescribe for people with Friedreich's Ataxia, also known as FA. This is known as an "observational" study, which collects health information about study participants without changing their medical care. Participants for this study will be found using a group called the Friedreich's Ataxia Global Clinical Consortium (FA GCC) UNIFIED Natural History Study (UNIFAI). The FA-GCC is a group of study research centers that helps provide clinical care for FA patients and also helps researchers learn more about how FA affects patients over a long time. The main objective of this study is to collect safety information in participants with FA from UNIFAI. Some of the participants in this study will be prescribed BIIB141 for the first time by their own doctors. Some of the participants will have started taking BIIB141 after joining UNIFAI, but less than 12 months before joining this study. The main questions researchers want to answer in this study are: * How many participants had serious adverse events (SAEs)? An adverse event is considered serious when it results in death, is life-threatening, causes lasting problems, or requires hospital care. * How many participants had adverse events (AEs) related to heart failure or liver damage caused by the drug? Researchers will also learn more about : • Why and when participants stopped treatment, left the study, or took more of the drug than was prescribed This study will be done as follows: * Participants will be screened to check if they can join the study. * After joining the study, the participants who had never started BIIB141 treatment before must start it within 6 months. Otherwise, all participants will take BIIB141 throughout this study as prescribed by their own doctor. * During the study, each participant's doctor will decide how often the participant visits the study research center to check on their health. This will be based on the doctor's own clinical judgment and what is recommended by the drug's label. * Data from the participants' regular visits to their doctor will be collected at 1 month, 2 months, 3 months, 6 months, 12 months, 24 months, 36 months, 48 months, and 60 months. * Each participant will be in the study for up to 5 years.
Eligibility Criteria
Key Inclusion Criteria: * Documented diagnosis of FA, including confirmation via genetic testing. * Participants aged 16 years and older at initiation of omaveloxolone treatment. For the omaveloxolone-naive cohort \- Initiating omaveloxolone treatment as per an approved label concurrent with enrolling in this study. For the omaveloxolone-non-naive cohort * Initiated omaveloxolone treatment as per an approved label less than 12 months prior to enrollment in this study * Prior to enrollment, maintained omaveloxolone treatment with no discontinuation of more than 60 days * Actively on treatment at the time of enrollment in this study * Treating physician is the study site principal investigator or sub-investigator * Study site confirms ability to provide required baseline data through medical record review, UNIFAI database, or other site-collected data * Enrolled in the UNIFAI study prior to initiation of omaveloxolone treatment Key Exclusion Criteria: * Received off-label prescription of omaveloxolone at any time. * Previously enrolled in a clinical trial of omaveloxolone. * Participating in a blinded interventional trial at the time of enrollment in the study; participants may participate in other clinical trials after baseline data are collected. Note: Other protocol-defined Inclusion/Exclusion criteria may apply.
Contact & Investigator
Medical Director
STUDY DIRECTOR
Biogen
Frequently Asked Questions
Who can join the NCT06623890 clinical trial?
This trial is open to participants of all sexes, aged 16 Years or older, studying Friedreich Ataxia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06623890 currently recruiting?
Yes, NCT06623890 is actively recruiting participants. Contact the research team at clinicaltrials@biogen.com for enrollment information.
Where is the NCT06623890 trial being conducted?
This trial is being conducted at Los Angeles, United States, Aurora, United States, Gainesville, United States, Philadelphia, United States and 10 additional locations.
Who is sponsoring the NCT06623890 clinical trial?
NCT06623890 is sponsored by Biogen. The principal investigator is Medical Director at Biogen. The trial plans to enroll 300 participants.